Charles Schwab Investment Management Inc. Boosts Holdings in Integra LifeSciences Holdings Corporation $IART

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Integra LifeSciences Holdings Corporation by 9.5%, now owning approximately 1.48% of the company valued at $25.2 million.
• Several institutional investors have significantly increased their holdings, with Sterling Capital Management growing theirs by 821.7% in the last quarter.
• Integra LifeSciences reported earnings of $0.45 EPS, exceeding estimates, but its revenue declined 0.6% year-over-year.

Charles Schwab Investment Management Inc. lifted its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 9.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,146,921 shares of the life sciences company's stock after acquiring an additional 99,348 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.48% of Integra LifeSciences worth $25,221,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Principal Financial Group Inc. grew its position in Integra LifeSciences by 2.5% during the first quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock valued at $9,542,000 after buying an additional 10,492 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in Integra LifeSciences during the first quarter valued at $251,000. Victory Capital Management Inc. grew its position in Integra LifeSciences by 1,067.6% during the first quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock valued at $3,254,000 after buying an additional 135,308 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after buying an additional 1,437 shares during the period. Finally, GAMMA Investing LLC grew its position in Integra LifeSciences by 3,595.1% during the first quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock valued at $5,140,000 after buying an additional 22,721 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

Shares of IART stock traded down $0.6050 during midday trading on Monday, hitting $14.2550. The company had a trading volume of 513,669 shares, compared to its average volume of 1,028,576. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -2.18, a PEG ratio of 0.84 and a beta of 1.16. Integra LifeSciences Holdings Corporation has a 52-week low of $11.06 and a 52-week high of $27.13. The company's 50 day simple moving average is $12.77 and its 200 day simple moving average is $16.32.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. The firm had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm's revenue was down .6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IART shares. JMP Securities decreased their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. JPMorgan Chase & Co. lowered their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company lowered their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus target price of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.